Close Menu

NEW YORK ─ Caris Life Sciences on Tuesday announced the submission of two premarket approval (PMA) applications to the US Food and Drug Administration for its MI Exome CDx and MI Transcriptome CDx sequencing assays.

The assays include important companion diagnostic biomarkers with therapy claims and detect all classes of alterations including genomic signatures for microsatellite instability (MSI), tumor mutation burden (TMB), and loss of heterozygosity (LOH), Irving, Texas-based Caris said.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.